This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
by Zacks Equity Research
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
ALKSPositive Net Change AMRNPositive Net Change KRYSPositive Net Change KROSNo Net Change
biotechs
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
by Zacks Equity Research
Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.
ALKSPositive Net Change AMRNPositive Net Change RYTMPositive Net Change KROSNo Net Change
biotechs
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
by Zacks Equity Research
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
BAYRYPositive Net Change RAREPositive Net Change VRNAPositive Net Change MREONegative Net Change
biotechnology biotechs medical pharmaceuticals
Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump
by Ekta Bagri
Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.
NVSPositive Net Change RHHBYNegative Net Change JNJPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
by Zacks Equity Research
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
AGENNegative Net Change AMRNPositive Net Change KALVNegative Net Change TAKPositive Net Change
biotechs medical
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
by Zacks Equity Research
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
BAYRYPositive Net Change VRNAPositive Net Change RXRXNegative Net Change RLYBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
by Ahan Chakraborty
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
by Zacks Equity Research
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
RHHBYNegative Net Change BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
GSK's Specialty Medicines Unit on a Strong Footing: Here's Why
by Kinjel Shah
GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
SNYPositive Net Change AZNPositive Net Change GSKPositive Net Change MRKPositive Net Change
biotechs
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck
by Zacks Equity Research
VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.
SNYPositive Net Change MRKPositive Net Change LLYPositive Net Change VRNAPositive Net Change
biotechs medical pharmaceuticals
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
by Zacks Equity Research
Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.
BAYRYPositive Net Change COGTNegative Net Change VRNAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy
by Zacks Equity Research
Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.
BAYRYPositive Net Change MBIONegative Net Change VRNAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
by Zacks Equity Research
Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.
SNYPositive Net Change BIIBPositive Net Change DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
by Zacks Equity Research
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
by Sundeep Ganoria
ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs earnings medical pharmaceuticals
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
by Ahan Chakraborty
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical oncology-screening pharmaceuticals
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
by Zacks Equity Research
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
REGNPositive Net Change VRTXPositive Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
by Zacks Equity Research
EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.
BMYPositive Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
by Zacks Equity Research
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
AZNPositive Net Change BMYPositive Net Change MRKPositive Net Change SMMTPositive Net Change
biotechs medical pharmaceuticals
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
by Zacks Equity Research
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.
RHHBYNegative Net Change BMYPositive Net Change NVOPositive Net Change PRTANegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
by Ahan Chakraborty
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
NVOPositive Net Change MRKPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Semiconductor and Biotech Drive EMCOR's Bookings?
by Sraddha Singha
EMCOR hits record RPOs as CHIPS and IRA acts drive long-term demand across semiconductor and biotech markets.
ACMNegative Net Change KBRNegative Net Change EMENegative Net Change
biotechs construction semiconductor
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
by Zacks Equity Research
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
AZNPositive Net Change EXELPositive Net Change PBYINegative Net Change SPRONegative Net Change
biotechs
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
by Sundeep Ganoria
HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.
JAZZPositive Net Change AXSMPositive Net Change HRMYNegative Net Change
biotechs marijuana medical
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study
by Zacks Equity Research
NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.
NVSPositive Net Change BAYRYPositive Net Change VRNAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals